Page last updated: 2024-12-08

13,14-dihydroprostaglandin e1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

13,14-Dihydroprostaglandin E1 (13,14-dihydro-PGE1) is a synthetic analog of prostaglandin E1 (PGE1), a naturally occurring hormone-like substance involved in various physiological processes.

**Here's why it's important for research:**

* **Increased Stability:** 13,14-dihydro-PGE1 is chemically more stable than PGE1. It is less susceptible to degradation by enzymes in the body, which makes it potentially more suitable for therapeutic use compared to the natural PGE1.

* **Pharmacological Properties:** 13,14-dihydro-PGE1 retains many of the pharmacological properties of PGE1, including its vasodilatory effects (widening blood vessels), its ability to protect the stomach lining, and its potential to stimulate the production of mucus.

* **Research Applications:** It's used in research to study the mechanisms of action of PGE1 and to investigate its potential therapeutic applications in conditions like:
* **Cardiovascular disease:** As a vasodilator, it could be beneficial in treating conditions like hypertension (high blood pressure) or heart failure.
* **Gastrointestinal disorders:** Its protective effects on the stomach lining could be helpful in treating ulcers and gastritis.
* **Inflammatory conditions:** PGE1 has anti-inflammatory properties, and 13,14-dihydro-PGE1 could be investigated for its potential in treating inflammatory disorders.

**However, it's crucial to note that:**

* **Clinical Studies:** Despite its promising preclinical research, the clinical application of 13,14-dihydro-PGE1 is still under investigation. More clinical trials are needed to determine its safety and efficacy in humans.

* **Potential Side Effects:** Like other prostaglandins, 13,14-dihydro-PGE1 may have side effects, such as nausea, diarrhea, or flushing.

Overall, 13,14-dihydro-PGE1 is an important research tool and a promising candidate for future drug development, but further research is needed before it can be considered for widespread clinical use.

13,14-dihydroprostaglandin E1: a PGE1 metabolite [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID161273
CHEMBL ID1476810
CHEBI ID89310
SCHEMBL ID5488727
MeSH IDM0190566

Synonyms (68)

Synonym
13,14-dihydroprostaglandin e1
CBIOL_002029
gtpl1946
BIO1_000804
BIO1_000315
BIO2_000529
BIO1_001293
BIO2_000049
13,14-dihydro-pge1
LMFA03010144
9-oxo-11r,15s-dihydroxy-prostanoic acid
13,14-dihydro-prostaglandin e1
IDI1_033799
BSPBIO_001329
NCGC00161302-02
NCGC00161302-01
KBIO3_000098
KBIO2_000049
KBIO2_005185
KBIO3_000097
KBIOSS_000049
KBIOGR_000049
KBIO2_002617
NCGC00161302-03
HMS1989C11
13,14-dihydro pge1
19313-28-1
BML2-B03
HMS1361C11
HMS1791C11
7-[(1r,2r,3r)-3-hydroxy-2-[(3s)-3-hydroxyoctyl]-5-oxocyclopentyl]heptanoic acid
cas_19313-28-1
pge0
bdbm82091
pge1, 13,14-dihydro
prostan-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,15s)-
unii-c1r6440ygw
dihydro-pge1
c1r6440ygw ,
prostaglandin e0
3-hydroxy-2-(3-hydroxyoctyl)-5-oxo-cyclopentaneheptanoic acid
chebi:89310 ,
CHEMBL1476810
SCHEMBL5488727
DPOINJQWXDTOSF-DODZYUBVSA-N
prostan-1-oic acid, 11,15-dihydroxy-9-oxo-, (11.alpha.,15s)-
u-23307
11.alpha.,15-dihydroxy-9-oxoprostanoic acid
11,15-dihydroxy-9-ketoprostanoic acid
(15s)-dihydroprostaglandin e1
dihydroprostaglandin e1
HMS3402C11
HMS3648B19
prostan-1-oic acid,11,15-dihydroxy-9-oxo-,(11a,15s)-
prostan-1-oic acid, 11,15-dihydroxy-9-oxo-, (11a,15s)-
13,14-dihydro-prostaglandin e1 (pge0)
11,15-dihydroxy-9-ketoprostanoate
3-hydroxy-2-(3-hydroxyoctyl)-5-oxo-cyclopentaneheptanoate
11a,15-dihydroxy-9-oxoprostanoate
11a,15-dihydroxy-9-oxoprostanoic acid
J-012500
Q27070768
sr-01000946404
SR-01000946404-1
prostan-1-oic acid,11,15-dihydroxy-9-oxo-, (11a,15s)-
DTXSID401317965
BP179596
PD021191
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
prostanoidThe family of natural prostaglandins and prostaglandin-like compounds including prostacyclins and thromboxanes.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1346427Human EP4 receptor (Prostanoid receptors)2000British journal of pharmacology, Aug, Volume: 130, Issue:8
Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's22 (81.48)18.2507
2000's1 (3.70)29.6817
2010's2 (7.41)24.3611
2020's2 (7.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.34 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.74 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (7.41%)5.53%
Reviews1 (3.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]